PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
Retrieved on:
Tuesday, January 17, 2023
Health, Infectious Diseases, Other Health, Pharmaceutical, Optical, Biotechnology, Annals of Plastic Surgery, Fungus, MD, NYSE, Bacteria, Burn, Organization, Patient, Gram-positive bacteria, NovaBay Pharmaceuticals, Hypochlorous acid, Doctor of Philosophy, Plastic surgery, Pharmaceutical industry, Harriott
PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States.
Key Points:
- PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States.
- “We expect wound care to be a larger part of our business in 2023 and we are excited to partner with PhaseOne Health to grow our sales in the coming year,” said Justin Hall, CEO of NovaBay Pharmaceuticals.
- While PhaseOne is primarily used for pre- and post-plastic surgery procedures, this coming year will bring an increased focus in the wound care market.
- We are looking forward to seeing PhaseOne Health continue to impact the wound care market and help to heal those in need.”